AFT PHARMACEUTICALS LIMITED — Director's Dealing 2021

Dec 21, 2021

==> picture [118 x 30] intentionally omitted <==

Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited;and	To NZX Limited;and	To NZX Limited;and	To NZX Limited;and	To NZX Limited;and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:
Director or senior managergivingdisclosure
Full name(s):		J Lb
		on am
Name of listed issuer:		AFT Pharmaceuticals Limited(AFT)
Name of related bodycorporate(if applicable):		Not applicable
Position held in listed issuer:		Director
Summary of acquisition or disposal of relevant interest(excluding specified derivatives)
Class ofaffected quotedfinancialproducts:		Fully-Paid OrdinaryShares in AFT
Nature of the affected relevant interest(s):		Power to control the exercise of the right to voteas trustee of the Rivers One Trust which holds thesharesin Rivers OneLimited
For that relevant interest-
Number heldinclass before acquisitionordisposal:		248,094
Number heldinclass afteracquisitionordisposal:		288,764
Current registeredholder(s):		N/A
Registeredholder(s) oncetransfers areregistered:		Rivers OneLimited
Details of transactionsgiving rise to acquisition or disposal
Total number of transactions to which notice relates:		1
Details of transactions requiring disclosure-
Date of transaction:
Nature of transaction:
Name of anyotherpartyorparties to the transaction(if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition ordisposal. If the consideration was not in cash and cannot be readily by converted into acash value,describe the consideration:
Number of financialproducts to which the transaction related:
If the issuer has a financial products trading policy that prohibits directors or seniormanagers from trading during any period without written clearance (a closed period) includethefollowing details—
Whether relevant interests were acquired or disposed of duringa closedperiod:		No
Whether prior written clearance was provided to allow the acquisition or disposal to proceedduringthe closed period:		Not applicable
Date of the prior writtenclearance (ifany):		Not applicable
Summary of other relevant interests after acquisition or disposal:
Class ofquoted financialproducts:
Nature of relevant interest:
_For that relevant interest,- _
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financialproducts (ifany):
Astatementastowhether the derivativeis cashsettled orphysically settled:
Maturity date of the derivative (ifany):
Expiry date of the derivative (ifany):
The price's specifiedterms (ifany):
Any other details needed to understand how the amount of the consideration payable underthe derivative or the value of the derivative is affected by the value of the underlyingfinancialproducts:
_For that derivative relevant interest,- _
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevantinterestinthe derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in thisdisclosure is correct and that I am duly authorised to make this disclosure by all persons forwhom itismade.
Signature of director or officer:Malcolm Tubby - CFO
Date ofsignature: